For a patient taking pravastatin 80 mg daily, with total cholesterol reduced from 269 mg/dL to 202 mg/dL, LDL reduced from 1.88 mmol/L to 1.15 mmol/L, and triglycerides increased from 2.51 mmol/L to 3.19 mmol/L, what management steps should be taken?

Management of Elevated Triglycerides Despite Good LDL Response on Pravastatin 80 mg

Switch to a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) and add targeted triglyceride management, as pravastatin 80 mg is already the maximum dose and represents only moderate-intensity therapy that cannot be further optimized. 1, 2

Why Change the Statin?

Your patient has achieved excellent LDL reduction (from 1.88 mmol/L to 1.15 mmol/L, approximately 39% reduction), but pravastatin has significant limitations:

• Pravastatin 80 mg is classified as moderate-intensity therapy (30-49% LDL reduction expected), not high-intensity 1
• The FDA label explicitly states: "For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment" 2
• You're already at maximum pravastatin dosing with no room for upward titration

The Triglyceride Problem

The concerning issue is the 27% increase in triglycerides (from 2.51 mmol/L to 3.19 mmol/L):

• Baseline triglycerides of 2.51 mmol/L (approximately 222 mg/dL) already indicated hypertriglyceridemia
• Current level of 3.19 mmol/L (approximately 282 mg/dL) represents moderate-to-severe hypertriglyceridemia
• This worsening is paradoxical but documented with pravastatin in certain populations, particularly those with metabolic syndrome or type IIB hyperlipidemia 3

Critical caveat: Research shows pravastatin may worsen hypertriglyceridemia and insulin resistance in patients with combined hyperlipidemia (type IIB), even while improving LDL cholesterol 3. This patient's pattern suggests underlying metabolic syndrome.

Recommended Management Algorithm

Step 1: Switch to High-Intensity Statin

• Atorvastatin 40-80 mg or rosuvastatin 20-40 mg 1
• These provide ≥50% LDL reduction and have better triglyceride-lowering effects than pravastatin
• The dose-response slope for pravastatin is weaker than atorvastatin or rosuvastatin 4

Step 2: Address Triglycerides Directly

According to 2018 ACC/AHA guidelines 1:

• Intensify lifestyle modifications immediately:

  • Limit sweets, sugar-sweetened beverages, and refined carbohydrates
  • Increase omega-3 rich fish intake
  • Aerobic exercise 3-4 sessions weekly, 40 minutes per session, moderate-to-vigorous intensity
  • Weight loss if overweight/obese (even 5-10% reduction helps significantly)

• Screen for metabolic syndrome (presence of ≥3 of 5 criteria: elevated waist circumference, elevated triglycerides, reduced HDL, elevated blood pressure, elevated fasting glucose) 1

• Consider adding fibrate or high-dose omega-3 fatty acids if triglycerides remain >200 mg/dL after statin switch and lifestyle optimization

Step 3: Reassess in 4-6 Weeks

• Check fasting lipid panel 2
• Assess liver enzymes and CK if symptomatic 2
• Evaluate adherence to lifestyle modifications

Important Clinical Pitfalls

1. Don't assume all statins are equivalent: Pravastatin has the weakest dose-response for LDL lowering among commonly used statins 4. The patient needs more potent therapy.

2. Don't ignore worsening triglycerides: Rising triglycerides on statin therapy suggest underlying metabolic dysfunction that requires specific attention beyond LDL management 3

3. Don't forget to assess for secondary causes: Rule out uncontrolled diabetes, hypothyroidism, excessive alcohol use, or medications that raise triglycerides

4. Metabolic syndrome is a risk-enhancing factor for ASCVD 1, making aggressive lipid management even more critical in this population

The combination of good LDL response but worsening triglycerides on maximum pravastatin strongly suggests this patient needs both more potent statin therapy and dedicated triglyceride management to optimize cardiovascular risk reduction.